Your browser is no longer supported. Please, upgrade your browser.
Settings
ONCT Oncternal Therapeutics, Inc. daily Stock Chart
ONCT [NASD]
Oncternal Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.27 Insider Own29.20% Shs Outstand15.36M Perf Week-18.91%
Market Cap42.99M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float11.31M Perf Month-22.03%
Income-36.60M PEG- EPS next Q- Inst Own17.70% Short Float0.33% Perf Quarter-20.36%
Sales2.50M P/S17.20 EPS this Y-101.10% Inst Trans85.81% Short Ratio0.92 Perf Half Y-47.65%
Book/sh0.68 P/B3.28 EPS next Y- ROA-153.50% Target Price- Perf Year-61.68%
Cash/sh- P/C- EPS next 5Y0.00% ROE-222.70% 52W Range2.24 - 6.29 Perf YTD-43.54%
Dividend- P/FCF- EPS past 5Y37.10% ROI-231.50% 52W High-64.55% Beta1.25
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin- 52W Low-0.45% ATR0.28
Employees11 Current Ratio2.30 Sales Q/Q20.00% Oper. Margin- RSI (14)30.79 Volatility9.22% 9.96%
OptionableNo Debt/Eq0.00 EPS Q/Q50.60% Profit Margin- Rel Volume3.90 Prev Close2.48
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume40.60K Price2.23
Recom3.00 SMA20-22.01% SMA50-21.23% SMA200-42.87% Volume158,444 Change-10.08%
Jun-30-20 08:00AM  
07:45AM  
May-20-20 08:00AM  
May-19-20 08:00AM  
May-07-20 08:00AM  
May-05-20 08:00AM  
May-01-20 08:00AM  
Mar-18-20 08:36AM  
Mar-16-20 04:05PM  
Mar-11-20 04:08PM  
08:00AM  
Feb-06-20 08:00AM  
Dec-12-19 06:00PM  
Dec-11-19 08:00AM  
Dec-09-19 08:00AM  
Dec-03-19 08:00AM  
Nov-21-19 08:00AM  
Nov-14-19 04:02PM  
Nov-11-19 08:00AM  
Nov-07-19 04:05PM  
Nov-05-19 08:00AM  
Oct-31-19 08:00AM  
Oct-03-19 08:00AM  
Sep-20-19 12:03PM  
Sep-17-19 04:05PM  
Sep-09-19 08:00AM  
Aug-28-19 04:01PM  
Aug-08-19 04:01PM  
Aug-06-19 08:00AM  
Aug-01-19 04:01PM  
Jun-10-19 08:00AM  
Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.